Oncolytics Biotech (NASDAQ:ONCY) Director Purchases $104,000.00 in Stock

Oncolytics Biotech Inc. (NASDAQ:ONCY) Director Bernd Seizinger acquired 100,000 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The shares were purchased at an average price of $1.04 per share, with a total value of $104,000.00. Following the completion of the acquisition, the director owned 466,991 shares of the company’s stock, valued at $485,670.64. This represents a 27.25% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Oncolytics Biotech Stock Performance

NASDAQ ONCY opened at $1.27 on Friday. Oncolytics Biotech Inc. has a 52 week low of $0.33 and a 52 week high of $1.51. The stock’s 50 day moving average price is $0.99 and its two-hundred day moving average price is $1.09. The stock has a market capitalization of $134.81 million, a price-to-earnings ratio of -4.54 and a beta of 0.97.

Oncolytics Biotech (NASDAQ:ONCY) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.02. On average, equities research analysts forecast that Oncolytics Biotech Inc. will post -0.28 EPS for the current year.

Hedge Funds Weigh In On Oncolytics Biotech

A number of hedge funds and other institutional investors have recently bought and sold shares of ONCY. Citadel Advisors LLC acquired a new position in Oncolytics Biotech during the third quarter worth approximately $535,000. Seeds Investor LLC boosted its stake in shares of Oncolytics Biotech by 17.8% during the 2nd quarter. Seeds Investor LLC now owns 223,767 shares of the company’s stock worth $173,000 after acquiring an additional 33,826 shares during the period. Finally, Scientech Research LLC acquired a new position in shares of Oncolytics Biotech during the 3rd quarter worth approximately $25,000. Institutional investors own 6.82% of the company’s stock.

Analyst Ratings Changes

ONCY has been the subject of a number of recent research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Oncolytics Biotech in a research note on Monday, December 29th. Zacks Research upgraded Oncolytics Biotech from a “hold” rating to a “strong-buy” rating in a report on Friday, October 17th. HC Wainwright increased their price target on Oncolytics Biotech from $5.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, November 17th. Finally, Wall Street Zen lowered Oncolytics Biotech from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.25.

About Oncolytics Biotech

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.